Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Merck & Eisai's cancer drug combo shows progress in some but not all key trials for gastroesophageal cancer.
Merck & Co. and Eisai's Phase 3 study of Keytruda and Lenvima in gastroesophageal cancer showed a statistically significant improvement in progression-free survival but did not meet the primary endpoint of overall survival.
The combination treatment's safety profile was consistent with previous studies.
The drugs are approved for several cancers and are under study for others.
16 Articles
La combinación de medicamentos contra el cáncer de Merck & Eisai muestra avances en algunos, pero no en todos, ensayos clave para el cáncer gastroesofágico.